Khosla, Seventure in $20m Eligo round

The round includes a $2m award from the Worldwide Innovation Challenge. Eligo will now look to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and grow its international team.

Khosla, a US-based venture house, stated it was attracted by the company's solution to targeting, with precision, the root causes of microbiome-associated diseases.

Seventure, meanwhile, raised the €160m Health for Life Capital fund two years ago specifically to support microbiome-focused companies. In July 2015, the firm provided a €2m seed funding round to Eligo.

Company
Founded in 2014, Eligo is a pre-clinical-stage synthetic biology company developing a biotherapeutics platform to bring precision medicine to the microbiome. The company produces biological nanobots, made of DNA and protein, that deliver a customised therapeutic impact to specific types of bacteria. 

Eligo is based in Paris and has raised $24m to date.

People
Khosla Ventures – Samir Kaul (partner).
Seventure Partners – Isabelle de Cremoux (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• France
• Venture
• France
• Seventure (SPEF)